Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)

This study has been completed.
Sponsor:
Collaborator:
Västerbotten County Council, Sweden
Information provided by (Responsible Party):
Anders Svenningsson, Umeå University
ClinicalTrials.gov Identifier:
NCT01719159
First received: October 25, 2012
Last updated: November 18, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)